Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
MIGDAL HA’EMEQ, Israel, March 08, 2016 -- Enzymotec Ltd. (NASDAQ:ENZY) (“Company”), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2015 with the U.S. Securities and Exchange Commission (“SEC”). The annual report on Form 20-F, which contains audited financial statements, can be accessed on the SEC’s website at http://www.sec.gov/ as well as via the Company’s investor relations website at http://ir.enzymotec.com/.
The Company will also deliver a hard copy of its annual report on Form 20-F, including its complete audited financial statements, free of charge, to its shareholders upon request to Oren Bryan at [email protected].
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures, and markets innovative bio-active lipid based nutritional ingredients and medical foods, driven by a deep core of cutting-edge, proprietary technologies intended to improve people’s health. For more information, visit www.enzymotec.com.
Company Contact: Enzymotec Ltd. Oren Bryan Chief Financial Officer Phone: +972747177177 [email protected] Investor Relations Contact: The Ruth Group Tram Bui / Lee Roth Phone: 646-536-7035 / 7012 [email protected] [email protected]
